CSL Behring, formerly a part of CSL Biotherapies, is Australia’s chosen national plasma fractionator and, under contract to Australia’s National Blood Authority, manufactures a complete range of life saving plasma-derived therapies for the treatment of the Australian community.
The range of plasma-derived therapies we manufacture for Australia is the largest manufactured in a single facility globally. It is also the only range in which every product is manufactured using processes that include at least two dedicated and complementary pathogen reduction steps. We are also the chosen national plasma fractionator of New Zealand, Hong Kong, Malaysia, Singapore and Taiwan.
In Australia, CSL Behring is a member of Medicines Australia (MA) and complies with the MA Code of Conduct. We have prepared the following reportable transfers of payment report for publication in accordance with Edition 18 of the MA Code of Conduct, and in a manner consistent with Australia’s Privacy legislation.
CSL Behring HCP transparency report 2015-16 PDF
CSL Behring HCP transparency report 2015-16 CSV
About CSL Behring
CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide.
CSL Behring therapies are used around the world to treat coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease, and neurological disorders in certain markets. The company’s products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in the newborn.
Our products are produced at facilities in Bern, Switzerland; Marburg, Germany; Kankakee, Illinois and Broadmeadows, Australia, in accordance with international safety and quality standards. Additionally, CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical company, which operates worldwide from its headquarters in Melbourne, Australia.
For more information about the company, please visit the global CSL Behring website.
CSL Delivering on Our Promise
100 years of CSL history – what we do and how we do it, with added perspective from our patients.
*In December 2012, CSL announced that its plasma product operations in Australia will take on the name of its global plasma business, CSL Behring, and that the Company’s vaccine, pharmaceutical and diagnostics business will operate under the newly created name of bioCSL, effective 1 January 2013.